Publications 2010

  1. Zhou J, Li PC, Kumarasamy N, Boyd M, Chen YM, Sirisanthana T, Sungkanuparph S, Oka S, Tau G, Phanuphak P, Saphonn V, Zhang FJ, Omar SF, Lee CK, Ditangco R, Merati TP, Lim PL, Choi JY, Law MG, Pujari S; TREAT Asia HIV Observational Database. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010 Jan;11(1):31-9. doi: 10.1111/j.1468-1293.2009.00738.x. Epub 2009 Jul 6.
  2. Puthanakit T and Bunupuradah T. Early versus deferred antiretroviral therapy in children in low and middle income countries. Curr Opin HIV AIDS. 2010 Jan;5(1):12-7. doi: 10.1097/COH.0b013e3283339b27.
  3. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIbrandomized trial. AIDS. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed.
  4. Arroyo MA, Phanuphak N, Krasaesub S, Sirivichayakul S, Assawadarachai V, Poltavee K, Pankam T, Ananworanich J, Paris R, Tovanabutra S, Kijak GH, McCutchan FE, Phanuphak P, Kim JH, de Souza M. HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses. 2010 Jan;26(1):5-12. doi: 10.1089/aid.2009.0150.
  5. Hemachandra A and Duncombe C. New antiviral therapy and its role in HIV treatment in Asia. Asian biomedicine. 2010 Jan;3(1):63-71.
  6. Gorowara M, Burger D, Hill A, Ruxrungtham K. Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. Curr Opin HIV AIDS. 2010 Jan;5(1):90-6. doi: 10.1097/COH.0b013e3283339caf.
  7. Gibb DM, Green H, Compagnucci A, Klein N, Lallemant M, Lyall H, Nadal D, Ananworanich J, Babiker A, Bunupuradah T, Darbyshire J, De Rossi A. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.
  8. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, Gorowara M, Vanprapar N, Leawsrisuk P, Suwan­lerk T, Boonrak P, Ruxrungtham K. Therapeutic drug monitoring of lopinavir in HIV-infected children receiving generic lopinavir/ritonavir adult tablets. Pediatr Infect Dis J. 2010 Jan;29(1):79-82. doi: 10.1097/INF.0b013e3181b21040.
  9. Bunupuradah T, Aurpibul L, Ananworanich J, Puthanakit T. The effectiveness of highly active antiret­roviral therapy among HIV-infected children in Asian countries. Asian Biomedicine. 2010 Jan; 3(1):89-100.
  10. Tavel JA; INSIGHT STALWART Study Group, Babiker A, Fox L, Gey D, Lopardo G, Markowitz N, Paton N, Wentworth D, Wyman N. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PLoS One. 2010 Feb 23;5(2):e9334. doi: 10.1371/journal.pone.0009334.
  11. Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U, Chaoniti N, Kaew-On P, Paris R, Ruxrungtham K, Valcour V; Southeast Asia Research Collaboration with Hawaii (SEARCH) 005 Protocol Team. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010 Feb;16(1):76-82. doi: 10.3109/13550280903493914.
  12. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA; Altair Study Group. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010 Mar 15;50(6):920-9. doi: 10.1086/650743.
  13. Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun S, Thantiworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, Ruxrungtham K, Lewin SR. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol. 2010 Mar;84(6):2657-65. doi: 10.1128/JVI.02124-09. Epub 2010 Jan 6.
  14. Ramautarsing R, Ohata PJ, Avihingsanon A, Kerr SJ, Ananworanich J, Chatbuddhiwet S, Duncombe C, Prasitsuebsai W, Puthanakit T, Ruxrungtham R. The 13th Bangkok International Symposium on HIV Medicine. HIV Ther. 2010 Mar;4(2):135-137.
  15. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P, Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, HirschelB, Ananworanich J; the HIV-NAT 013 Study Team. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors. Int J Infect Dis. 2010 Apr;14(4):e311-6. doi: 10.1016/j.ijid.2009.05.017. Epub 2009 Aug 21.
  16. Tieu HV, Phanuphak N, Ananworanich J, Vatanparast R, Jadwattanakul T, Pharachetsakul N, Mingkwanrungrueng P, Buajoom R, Teeratakulpisarn S, Teeratakulpisarn N, Methajittiphun P, Hammer SM, Ann Chiasson M, Phanuphak P. Acceptability of male circumcision for the prevention of HIV among high-risk heterosexual men in Thailand. Sex Transm Dis. 2010 Jun;37(6):352-5. doi: 10.1097/OLQ.0b013e3181c9963a.
  17. Ramautarsing R, Ananworanich J. Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. AIDS Res Ther. 2010 Jun 23;7:18. doi: 10.1186/1742-6405-7-18.
  18. Hoare A, Kerr SJ, Ruxrungtham K, Ananworanich J, Law MG, Cooper DA, Phanuphak P, Wilson DP. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One. 2010 Jun 8;5(6):e10981. doi: 10.1371/journal.pone.0010981.
  19. Lampe FC, Duprez DA, Kuller LH, Tracy R, Otvos J, Stroes E, Cooper DA, Hoy J, Paton NI, Friis-Møller N, Neuhaus J, Liappis AP, Phillips AN; INSIGHT SMART Study Group. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Jul;54(3):275-84.
  20. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA; INSIGHT ESPRIT & SILCAAT study groups. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS. 2010 Jul 31;24(12):1877-86. doi: 10.1097/QAD.0b013e32833b1b26.
  21. Kerr SJ, Ananworanich J, Ruxrungtham K. Changing evidence on HIV treatment and prevention strategies: Implications and advice for healthcare workers and National Treatment Programs in Asia. Asian Biomedicine. 2010 Aug; 4(4): 501-503.
  22. Duncombe C, Kerr SJ, Liddy J, Avihingsanon A, Ruxrungtham K, Phanuphak P. Efficacy and tolerability of zidovudine 200 mg BID as part of combination antiretroviral therapy for 96 weeks. J Acquir Immune Defic Syndr. 2010 Aug;54(5):e19-20. doi: 10.1097/QAI.0b013e3181ed1823.
  23. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P, for The Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine. 2010 Aug;4(4):515-528.
  24. Puthanakit T, Tangsathapornpong A, Ananworanich J, Wongsawat J, Suntrattiwong P, Wittawatmongkol O, Mekmullica J, Waidab W, Bhakeecheep S, Chokephaibulkit K, for the Thai National HIV Guidelines Working Group. Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010. Asian Biomedicine. 2010 Aug; 4(4): 505-513.
  25. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW; For the INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positivepersons. Neurology. 2010 Sep 7;75(10):864-73. doi: 10.1212/WNL.0b013e3181f11bd8. Epub 2010 Aug 11.
  26. Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC; on behalf of The TREAT Asia HIV Observational Database. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010 Sep;11(8):519-29. doi: 10.1111/j.1468-1293.2010.00822.x. Epub 2010 Mar 21.
  27. Audsley J, Littlejohn M, Yuen LK, Sasadeusz J, Ayres A, Desmond C, Spelman T, Lau G, Matthews GV, Avihingsanon A, Seaberg E, Philp F, Saulynas M, Ruxrungtham K, Dore GJ, Locarnini SA, Thio CL, Lewin SR, Revill PA. Prevalence of HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing Virology. Virology. 2010 Sep 30;405(2):539-47. doi: 10.1016/j.virol.2010.06.038. Epub 2010 Jul 23.
  28. Hemachandra A, Puls RL, Kerr S, Sirivichayakul S, Thantiworasit P, Ubolyam S, Cooper DA, Emery S, Phanuphak P, Kelleher A and Ruxrungtham K. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin. 2010 Oct;6(10):835-40. doi: 10.4161/hv.6.10.12635. Epub 2010 Oct 1.
  29. Wongsawat J, Puthanakit T, Kanjanavanit S, Hansudewechakul R, Ngampiyaskul C, Kerr SJ, Ubolyam S, Suwanlerk T, Kosalaraksa P, Luesomboon W, Ngo-Giang-Huong N, Chandara M, Saphonn V, Ruxrungtham K, Ananworanich J; on behalf of the PREDICT Study Group. CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2010 Oct;29(10):966-8. doi: 10.1097/INF.0b013e3181e0554c.
  30. Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010 Oct 1;51(7):855-64. doi: 10.1086/656363.
  31. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Siridanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; on behalf of the HIV-NAT 086 study team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25.
  32. Landolt NK, Phanuphak N, Chaithongwongwatthana S, Ananworanich J. Sexual life and Contraception in People Living with HIV. Asian Biomedicine. 2010 Oct; 4 (5): 691-701.
  33. Hansudewechakul R, Sirisanthana V, Kurniati N, Puthanakit T, Lumbiganon P, Saphonn V, Yusoff NK, Kumarasamy N, Fong SM, Nallusamy R, Srasuebkul P, Law M, Sohn AH, Chokephaibulkit K; TREAT Asia Pediatric HIV Observational Database. Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr. 2010 Dec;55(4):503-9. doi: 10.1097/QAI.0b013e3181f5379a.
  34. Rongkavilit C, Naar-King S, Kaljee LM, Panthong A, Koken JA, Bunupuradah T, Parsons JT. Applying the Information-Motivation-Behavioral Skills Model in Medication Adherence among Thai Youth Living with HIV: A Qualitative Study. AIDS Patient Care STDS. 2010 Dec;24(12):787-94. doi: 10.1089/apc.2010.0069. Epub 2010 Nov 22.
  35. Petoumenos K, Hui E, Kumarasamy N, Kerr SJ, Choi JY, Chen YM, Merati T, Zhang F, Lim PL, Sungkanuparph S, Pujari S, Ponnampalavanar S, Ditangco R, Lee CK, Grulich A, Law MG; TREAT Asia HIV Observational Database. Cancers in the TREAT Asia HIV Observational Database (TAHOD): A retrospective analysis of risk factors. J Int AIDS Soc. 2010 Dec 10;13:51. doi: 10.1186/1758-2652-13-51.
  36. Ananworanich J, Apornpong T, Kosalaraksa P, Jaimulwong T, Hansudewechakul R, Pancharoen C, Bunupuradah T, Chandara M, Puthanakit T, Ngampiyasakul C, Wongsawat J, Kanjanavanit S, Luesomboon W, Klangsinsirikul P, Ngo-Giang-Huong N, Kerr SJ, Ubolyam S, Mengthaisong T, Gelman RS, Pattanapanyasat K, Saphonn V, Ruxrungtham K, Shearer WT; PREDICT Study Group. Characteristics of lymphocyte subsets in HIV-infected, long-term nonprogressor, and healthy Asian children through 12 years of age. J Allergy Clin Immunol. 2010 Dec;126(6):1294-301.e10. doi: 10.1016/j.jaci.2010.09.038.
  37. Ananworanich J, Apornpong T, Kosalaraksa P, Jaimulwong T, Hansudewechakul R, Pancharoen C, Bunupuradah T, Chandara M, Puthanakit T, Ngampiyasakul C, Wongsawat J, Kanjanavanit S, Luesomboon W, Klangsinsirikul P, Ngo- Giang-Huong N, Kerr SJ, Ubolyam S, Mengthaisong T, Gelman RS, Pattanapanyasat K, Saphonn V, Ruxrungtham K, Shearer WT, on behalf of the PREDICT study group. Lymphocyte subsets in healthy, HIV-infected, and long term nonprogressor Asian children through 12 years of age. J Allergy Clin Immunol. 2010 Dec;126(6):1294-301.e10. doi: 10.1016/j.jaci.2010.09.038.
  38. Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL, Kumarasamy N, Choi JY, Merati TP, Yunihastuti E, Oka S, Kamarulzaman A, Phanuphak P, Lee CK, Li PC, Pujari S, Saphonn V, Law MG. Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infect Dis. 2010 Dec 23;10:361. doi: 10.1186/1471-2334-10-361.
  39. Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviralnaive HIV-HBV coinfection in Thailand. Antivir Ther. 2010;15(6):917-22. doi: 10.3851/IMP1645.
  40. Hill A, Ananworanich J, Calmy A. Improving antiretroviral treatment access in low and middle income countries in a time of economic crisis. The Open Infectious Diseases Journal. 2010:4:85-91.